Yale’s David Spiegel in­spires an­oth­er im­muno-on­col­o­gy R&D spin­out fo­cused on An­ti­body Re­cruit­ing Mol­e­cules

A year ago, a joint ven­ture be­tween Bris­tol-My­ers Squibb and Al­lied Minds picked up some im­muno-on­col­o­gy mol­e­cules from the lab of Yale’s David Spiegel. Now his work on An­ti­body Re­cruit­ing Mol­e­cules — which lure in an­ti­bod­ies to a spe­cif­ic sur­face pro­tein in or­der to de­stroy dis­eased cells — is be­ing used to spin out a new biotech called Kleo Phar­ma­ceu­ti­cals, which plans to go af­ter can­cer and in­fec­tious dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.